FDA Approval: Repotrectinib, a ROS1 and NTRK inhibitor

Lung Cancer Considered
30/11/2023 37 min
FDA Approval: Repotrectinib, a ROS1 and NTRK inhibitor

Listen "FDA Approval: Repotrectinib, a ROS1 and NTRK inhibitor"

Descargar episodio Ver en sitio original

Episode Synopsis

Lung Cancer Considered host Dr. Stephen Liu moderates a discussion on the November 15, 2023, US FDA approval of repotrectinib for advanced NSCLC with a ROS1 gene fusion based on the single-arm, multi-cohort TRIDENT-1 trial.
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA